$1.20
-0.01 (-0.83%)
Open$1.21
Previous Close$1.21
Day High$1.21
Day Low$1.16
52W High$24.30
52W Low$1.10
Volume—
Avg Volume458.3K
Market Cap2.93M
P/E Ratio—
EPS$-9.28
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,279.2% upside
Current
$1.20
$1.20
Target
$16.55
$16.55
$10.07
$16.55 avg
$19.24
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 206.03M | 953.7K | 857.2K |
| Net Income | -33,909,764 | 90.7K | 81.5K |
| Profit Margin | -16.5% | 9.5% | 9.5% |
| EBITDA | -33,453,743 | 169.7K | 158.3K |
| Free Cash Flow | — | 104.6K | 58.4K |
| Rev Growth | +102.9% | +23.3% | +22.6% |
| Debt/Equity | — | 0.69 | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.68 | -0.45% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $412.84 | -1.20% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.12 | -0.01% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $508.33 | -1.57% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.64 | -0.29% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.29 | +0.07% | 35.2 | 28.41B |